JP2022527334A5 - - Google Patents

Info

Publication number
JP2022527334A5
JP2022527334A5 JP2021558768A JP2021558768A JP2022527334A5 JP 2022527334 A5 JP2022527334 A5 JP 2022527334A5 JP 2021558768 A JP2021558768 A JP 2021558768A JP 2021558768 A JP2021558768 A JP 2021558768A JP 2022527334 A5 JP2022527334 A5 JP 2022527334A5
Authority
JP
Japan
Prior art keywords
administered
pharmaceutical composition
antigen
binding fragment
oleculumb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021558768A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527334A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/053110 external-priority patent/WO2020202038A1/en
Publication of JP2022527334A publication Critical patent/JP2022527334A/ja
Publication of JP2022527334A5 publication Critical patent/JP2022527334A5/ja
Priority to JP2025166226A priority Critical patent/JP2026031542A/ja
Pending legal-status Critical Current

Links

JP2021558768A 2019-04-02 2020-04-01 腫瘍を処置するための抗cd73、抗pd-l1抗体及び化学療法 Pending JP2022527334A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025166226A JP2026031542A (ja) 2019-04-02 2025-10-02 腫瘍を処置するための抗cd73、抗pd-l1抗体及び化学療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962828177P 2019-04-02 2019-04-02
US62/828,177 2019-04-02
PCT/IB2020/053110 WO2020202038A1 (en) 2019-04-02 2020-04-01 Anti-cd73, anti-pd-l1 antibodies and chemotherapy for treating tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025166226A Division JP2026031542A (ja) 2019-04-02 2025-10-02 腫瘍を処置するための抗cd73、抗pd-l1抗体及び化学療法

Publications (2)

Publication Number Publication Date
JP2022527334A JP2022527334A (ja) 2022-06-01
JP2022527334A5 true JP2022527334A5 (cg-RX-API-DMAC7.html) 2023-11-08

Family

ID=72663659

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021558768A Pending JP2022527334A (ja) 2019-04-02 2020-04-01 腫瘍を処置するための抗cd73、抗pd-l1抗体及び化学療法
JP2025166226A Pending JP2026031542A (ja) 2019-04-02 2025-10-02 腫瘍を処置するための抗cd73、抗pd-l1抗体及び化学療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025166226A Pending JP2026031542A (ja) 2019-04-02 2025-10-02 腫瘍を処置するための抗cd73、抗pd-l1抗体及び化学療法

Country Status (13)

Country Link
US (1) US20200317803A1 (cg-RX-API-DMAC7.html)
EP (1) EP3947447A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022527334A (cg-RX-API-DMAC7.html)
KR (1) KR20210148253A (cg-RX-API-DMAC7.html)
CN (2) CN119857140A (cg-RX-API-DMAC7.html)
AU (2) AU2020254100B9 (cg-RX-API-DMAC7.html)
CA (1) CA3134671A1 (cg-RX-API-DMAC7.html)
EA (1) EA202192587A1 (cg-RX-API-DMAC7.html)
IL (1) IL286504A (cg-RX-API-DMAC7.html)
MA (1) MA55558A (cg-RX-API-DMAC7.html)
SG (1) SG11202110694RA (cg-RX-API-DMAC7.html)
TW (1) TW202102545A (cg-RX-API-DMAC7.html)
WO (1) WO2020202038A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL301376A (en) * 2020-09-23 2023-05-01 Medimmune Llc Treatment methods using anti-cd73 and anti-pd-l1 antibodies and chemotherapy
AU2023252914A1 (en) 2022-04-13 2024-10-17 Arcus Biosciences, Inc. Combination therapy for treating trop-2 expressing cancers
CN120019073A (zh) * 2022-05-26 2025-05-16 天境生物科技(上海)有限公司 一种治疗实体瘤的方法
AU2023403103A1 (en) * 2022-12-01 2025-07-10 Medimmune Limited Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
RS62003B2 (sr) 2014-11-10 2025-01-31 Medimmune Ltd Vezujući molekuli specifični za cd73 i njihove upotrebe
AU2017228470A1 (en) * 2016-03-04 2018-08-30 Bristol-Myers Squibb Company Combination therapy with anti-CD73 antibodies
FI3922279T3 (fi) * 2016-08-30 2025-02-04 Dana Farber Cancer Inst Inc Lääkkeenantokoostumuksia ja niiden käyttötapoja
MX2019015885A (es) * 2017-06-22 2020-09-10 Novartis Ag Moleculas de anticuerpo que se unen a cd73 y usos de las mismas.

Similar Documents

Publication Publication Date Title
JP2025020147A5 (cg-RX-API-DMAC7.html)
CN100363004C (zh) 喹唑啉衍生物zd6474组合吉西他滨在制备药物中的用途
JP2023526451A5 (cg-RX-API-DMAC7.html)
JP2014512356A5 (cg-RX-API-DMAC7.html)
JP2021510725A5 (cg-RX-API-DMAC7.html)
JP2012506448A5 (cg-RX-API-DMAC7.html)
JP2016528162A5 (cg-RX-API-DMAC7.html)
JP2012509889A5 (cg-RX-API-DMAC7.html)
ME02470B (me) Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekom
JP2003533485A5 (cg-RX-API-DMAC7.html)
Takahashi et al. Phase I trial evaluating the safety of preoperative gemcitabine/nab-paclitaxel with concurrent radiation therapy for borderline resectable pancreatic cancer
Sugawara et al. Randomized phase II trial of uracil/tegafur and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-small-cell lung cancer: NJLCG 0601
JP2025504278A5 (cg-RX-API-DMAC7.html)
JP2019038797A5 (cg-RX-API-DMAC7.html)
JP2024513247A5 (cg-RX-API-DMAC7.html)
Kunisaki et al. Biweekly Docetaxel and S-1 combination chemotherapy as first-line treatment for elderly patients with advanced gastric cancer
JP2007504259A5 (cg-RX-API-DMAC7.html)
JP2021529777A5 (cg-RX-API-DMAC7.html)
JP2020520385A5 (cg-RX-API-DMAC7.html)
Hu et al. Current status of CPT and its analogues in the treatment of malignancies
JP2016522826A5 (cg-RX-API-DMAC7.html)
Lee et al. Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma
Tamura et al. Phase I/II study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer
JP2018522030A5 (cg-RX-API-DMAC7.html)
CN119822979A (zh) 一种用于制备肿瘤治疗药物的化合物及其药物组合物